- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Attention defecit hyperactivity disorder (ADHD)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Lisdexamfetamine – March 2020
Lisdexamfetamine: Capsule containing lisdexamfetamine dimesilate 20mg, 30mg, 40mg, 50mg, 60mg, 70mg; Vyvanse®
Last updated
3 July 2020